½ÃÀ庸°í¼­
»óǰÄÚµå
1382480

¼¼°èÀÇ ÀڱñÙÁ¾ ÀýÁ¦¼ú ½ÃÀå - Á¦Ç°, À¯Çü, ÃÖÁ¾ ¿ëµµ ¹× ¿¹Ãø(-2032³â)

Myomectomy Market - By Product, By Type, By End-use - Global Forecast to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 248 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ÀڱñÙÁ¾ ÀýÁ¦¼ú ½ÃÀå ±Ô¸ð´Â ·Îº¿ º¸Á¶ ¼ö¼ú ¹× Àúħ½À ¼ö¼ú°ú °°Àº ÷´Ü ¼ö¼ú ±â¼úÀÇ Áö¼ÓÀûÀÎ °³¹ß ¹× äÅÃÀ¸·Î 2023³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 8.6%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

·Îº¿ º¸Á¶ ¼ö¼ú, º¹°­°æ ¼ö¼ú, ÷´Ü ¿µ»ó ±â¼úÀÇ °íÁýÀûÈ­¿Í °°Àº ±â¼ú Çõ½ÅÀº ÀڱñÙÁ¾ ÀýÁ¦¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ º¯È­½Ã۰í ÀÖÀ¸¸ç, Á¤È®µµ¸¦ ³ôÀ̰í ħ½À¼ºÀ» ³·Ã߸ç ȸº¹ ½Ã°£À» ´ÜÃàÇÏ¿© ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¿Ü°úÀÇ»çµéÀº ¼ö¼ú Áß ´õ ³ªÀº °¡½Ã¼º°ú ÅëÁ¦·ÂÀ» ÅëÇØ ÇýÅÃÀ» ¾ò°í ÀÖÀ¸¸ç, ±â¼úÀûÀ¸·Î Áøº¸µÈ Á¢±Ù ¹æ½ÄÀ» ¼±È£ÇÏ´Â °æÇâÀÌ ´õ¿í °­ÇØÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 11¿ù ¿Ã¸²Çª½º´Â TROKAMED GmbH°¡ Á¦Á¶ÇÑ ÀúÀ§Çè ÀÚ±ÃÀûÃâ¼ú ¹× ÀڱñÙÁ¾ ÀýÁ¦¼úÀ» ¹Þ´Â ȯÀÚ¸¦ À§ÇÑ »õ·Î¿î Àúħ½ÀÀû ¼ö¼ú ´ëü ÀåºñÀÎ ¸ð·¹¼Ö·ç¼Ç(TM) ÆÄ¿ö ¸ð¼¿·¹ÀÌÅÍ(Power Morcellator)¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ½ÃÀåÀº ÇコÄÉ¾î ºÐ¾ßÀÇ º¯È­ ¼Ó¿¡¼­ ²ÙÁØÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

ÀڱñÙÁ¾ ÇÙÃâ¼ú »ê¾÷Àº Á¦Ç° À¯Çü, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªÀ¸·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î º¸¸é, °íÁ¶ÆÄ ¸Þ½º ½ÃÀå ±Ô¸ð´Â 2023-2032³â 8.2%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °íÁ¶ÆÄ ¸Þ½º´Â ÃâÇ÷À» ÁÙÀ̰í ȯÀÚÀÇ È¸º¹À» ÃËÁøÇϱâ À§ÇØ ÀڱñÙÁ¾ ÀýÁ¦¼ú¿¡¼­ Á¤È®¼º°ú ÃÖ¼Ò Ä§½À¼ºÀ» Á¦°øÇϱ⠶§¹®¿¡ °¢±¤À» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ¿Ü°úÀû °³ÀÔÀ» ÃÖÀûÈ­Çϱâ À§ÇØ Ã·´Ü ±â¼úÀ» ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, ¼ö¼ú °á°ú¸¦ °³¼±Çϱâ À§ÇØ ¿­ È®»êÀ» ÁÙÀÌ°í ½Ã°¢È­¸¦ °³¼±Çϱâ À§ÇØ °íÁ¶ÆÄ ¸Þ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾ ¿ëµµº°·Î´Â ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ºÎ¹®ÀÇ ÀڱñÙÁ¾ ÀýÁ¦¼ú »ê¾÷Àº 2023³âºÎÅÍ 2032³â±îÁö 8.5%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÔ¿ø ºñ¿ë Àý°¨°ú ȸº¹ ½Ã°£ ´ÜÃàÀ¸·Î ÀÎÇØ ¿Ü·¡ ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ASC´Â ±âÁ¸ º´¿ø ȯ°æ¿¡ ºñÇØ ÀڱñÙÁ¾ ÀýÁ¦¼ú¿¡ Æí¸®ÇÏ°í ºñ¿ë È¿À²ÀûÀΠȯ°æÀ» Á¦°øÇÕ´Ï´Ù. ȯÀÚ¿¡°Ô Á¦°øµÇ´Â Á¢±Ù¼º°ú È¿À²¼º, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿¡°Ô Á¦°øµÇ´Â °£¼ÒÈ­µÈ ¿öÅ©Ç÷ο쿡 ´ëÇÑ Á¢±Ù¼ºÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Áö¿ªº°·Î º¸¸é, ¾Æ½Ã¾ÆÅÂÆò¾ç ÀڱñÙÁ¾ ÀýÁ¦¼ú ½ÃÀåÀº 2022³â »ó´çÇÑ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÎÁöµµ Áõ°¡, ÀڱñÙÁ¾ À¯º´·ü Áõ°¡, ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ 2032³â±îÁö ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °í±Þ ÀÇ·á ¼Ö·ç¼ÇÀ» ã´Â ¿©¼º Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀڱñÙÁ¾ ÀýÁ¦¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â ƯÈ÷ Áß±¹°ú Àεµ¿¡¼­ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À¯¸®ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºêÀÇ À¯ÀÔ°ú Çõ½ÅÀûÀÎ ¼ö¼ú ±â¼ú äÅÃÀÇ ±ÞÁõÀº Áö¿ª »ê¾÷ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀڱñÙÁ¾ ÀýÁ¦¼ú ¾÷°è ÀλçÀÌÆ®

  • COVID-19ÀÇ ¿µÇ⠺м®
  • »ýÅÂ°è ºÐ¼®
  • ±â¼ú »óȲ
  • ±ÔÁ¦ »óȲ
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©£¦°úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
    • Medtronic
    • Stryker Corporation
    • CONMEDCorporation
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå ÀڱñÙÁ¾ ÀýÁ¦¼ú ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Ç°º°

  • ÁÖ¿ä µ¿Çâ : Á¦Ç°º°
  • º¹°­°æ ÆÄ¿ö ¸ð¼¿·¹ÀÌÅÍ
  • Çϸð´Ð ¸Þ½º
  • º¹°­°æ ½Ç·¯
  • ±âŸ

Á¦6Àå ÀڱñÙÁ¾ ÀýÁ¦¼ú ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Çüº°

  • ÁÖ¿ä µ¿Çâ : À¯Çüº°
  • º¹½Ä ÀڱñÙÁ¾ ÀýÁ¦¼ú
  • ÀڱðæÇÏ ÀڱñÙÁ¾ ÀýÁ¦¼ú
  • º¹°­°æÇÏ ÀڱñÙÁ¾ ÀýÁ¦¼ú

Á¦7Àå ÀڱñÙÁ¾ ÀýÁ¦¼ú ½ÃÀå Ã߻ꡤÁÖ¿ä µ¿Çâ ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾»ç¿ëÀÚº°
  • º´¿ø ¹× Ŭ¸®´Ð
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦8Àå ÀڱñÙÁ¾ ÀýÁ¦¼ú ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½ºÀ§½º
    • ³×´ú¶õµå
    • µ§¸¶Å©
    • Æú¶õµå
    • ½º¿þµ§
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ´ºÁú·£µå
    • ű¹
    • º£Æ®³²
    • Àεµ³×½Ã¾Æ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • Ä¥·¹
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ÅÍŰ

Á¦9Àå ±â¾÷ °³¿ä

  • Medtronic
  • Stryker Corporation
  • CONMEDCorporation
  • INSIGHTEC
  • CooperSurgical Inc.
  • Hologic, Inc.
  • Intuitive Surgical
  • Karl Storz
  • B. Braun Melsungen AG
  • Minerva Surgical Inc
LSH 23.11.29

Myomectomy Market size is poised to expand at 8.6% CAGR from 2023-2032 driven by the ongoing development and adoption of advanced surgical technologies, such as robotic-assisted and minimally invasive techniques. Innovations, including robotic-assisted surgery, laparoscopy, and higher integration of advanced imaging techniques are transforming the demand for myomectomy procedures to offer increased precision, reduced invasiveness, and shorter recovery times for enhanced patient outcomes.

Moreover, surgeons are benefiting from improved visualization and control during the procedures, further contributing to the growing preference for technologically advanced approaches. For instance, in November 2022, Olympus introduced its new minimally invasive surgery alternative, moresolution™ Power Morcellator, produced from TROKAMED GmbH for patients undergoing low-risk hysterectomy or myomectomy. With the rising transformation of the healthcare sector, the market is poised to witness steady growth.

The myomectomy industry is segmented into product type, end-use, and region.

Based on product type, the market size from the harmonic scalpel segment is likely to showcase 8.2% CAGR from 2023-2032. Harmonic scalpel has gained prominence as it offers precision and minimal invasiveness in myomectomy procedures for reducing blood loss and enhancing patient recovery. With healthcare providers prioritizing advanced technologies to optimize surgical interventions, the demand for harmonic scalpels is expected to rise to offer reduced thermal spread and improved visualization for improved surgical outcomes.

In terms of end-use, the myomectomy industry from the ambulatory surgical centers (ASC) segment is set to attain 8.5% CAGR between 2023 and 2032. The increasing preference for outpatient procedures due to reduced hospitalization costs and quicker recovery times will contribute to the segment growth. ASCs offer more convenient and cost-effective environment for myomectomy procedures compared to traditional hospital settings. The accessibility and efficiency offered to patients and the access to streamlined workflow to healthcare providers will add to the segment growth.

Regionally, the Asia Pacific myomectomy market held sizable revenue share in 2022 and is estimated to record steady growth through 2032 owing to increasing awareness, the rising prevalence of uterine fibroids, and higher advancements in healthcare infrastructure. Additionally, with the growing female population seeking advanced healthcare solutions, the demand for myomectomy procedures is particularly rising in China and India. The influx of favorable government initiatives and the surging adoption of innovative surgical technologies will further propel the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & workings
  • 1.3 Forecast calculations
  • 1.4 Data Sources
    • 1.4.1 Primary
    • 1.4.2 Secondary
      • 1.4.2.1 Paid sources
      • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Global myomectomy market 360 degree synopsis, 2018 - 2032
  • 2.2 Regional trends
  • 2.3 Product trends
  • 2.4 Type trends
  • 2.5 End-use trends

Chapter 3 Myomectomy Industry Insights

  • 3.1 COVID- 19 impact analysis
  • 3.2 Industry ecosystem analysis
  • 3.3 Technology landscape
  • 3.4 Regulatory landscape
  • 3.5 Industry impact forces
    • 3.5.1 Growth drivers
      • 3.5.1.1 Growing prevalence of uterine fibroids
      • 3.5.1.2 Increasing adoption of technological advanced devices for myomectomy procedures
      • 3.5.1.3 Growing demand for minimally invasive procedures
      • 3.5.1.4 Improved healthcare infrastructure in developing countries
    • 3.5.2 Industry pitfalls & challenges
      • 3.5.2.1 High cost of medical devices
      • 3.5.2.2 Complications associated with the procedure
  • 3.6 Growth potential analysis
    • 3.6.1 By product
    • 3.6.2 By type
    • 3.6.3 By end-use
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
    • 4.1.1 Medtronic
    • 4.1.2 Stryker Corporation
    • 4.1.3 CONMEDCorporation
  • 4.2 Competitive analysis of major market players, 2022
  • 4.3 Competitive positioning matrix, 2022
  • 4.4 Strategic outlook matrix, 2022

Chapter 5 Myomectomy Market Estimates and Forecast, By Product (Revenue and Volume)

  • 5.1 Key trends, by product
  • 5.2 Laparoscopic power morcellators
  • 5.3 Harmonic scalpel
  • 5.4 Laparoscopic sealer
  • 5.5 Others

Chapter 6 Myomectomy Market Estimates and Forecast, By Type (Revenue)

  • 6.1 Key trends, by type
  • 6.2 Abdominal myomectomy
  • 6.3 Hysteroscopic myomectomy
  • 6.4 Laparoscopic myomectomy

Chapter 7 Myomectomy Market Estimates and Forecast, By End-use (Revenue)

  • 7.1 Key trends, by end-use
  • 7.2 Hospitals & clinics
  • 7.3 Ambulatory surgical centers
  • 7.4 Others

Chapter 8 Myomectomy Market Estimates and Forecast, By Region (Revenue and Volume)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Switzerland
    • 8.3.7 The Netherlands
    • 8.3.8 Denmark
    • 8.3.9 Poland
    • 8.3.10 Sweden
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 New Zealand
    • 8.4.7 Thailand
    • 8.4.8 Vietnam
    • 8.4.9 Indonesia
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Colombia
    • 8.5.5 Chile
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Turkey

Chapter 9 Company Profiles

  • 9.1 Medtronic
  • 9.2 Stryker Corporation
  • 9.3 CONMEDCorporation
  • 9.4 INSIGHTEC
  • 9.5 CooperSurgical Inc.
  • 9.6 Hologic, Inc.
  • 9.7 Intuitive Surgical
  • 9.8 Karl Storz
  • 9.9 B. Braun Melsungen AG
  • 9.10 Minerva Surgical Inc
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦